AZN - Ticker AI Digest

AstraZeneca PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (AZN) 1
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
AZN 06:01
AstraZeneca PLC
Agreement with US Govt to lower medicine prices
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
Approvals 2
AZN 06:01
AstraZeneca PLC
Koselugo (selumetinib) approved in the EU
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Koselugo (selumetinib) has been approved in the European Union (EU) for treating symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1). The approval is based on positive results from the KOMET Phase III trial, which demonstrated a 20% objective response rate in tumor size reduction compared to 5% with placebo. This marks a significant advancement in addressing unmet needs for adult NF1 patients, as PN can cause severe symptoms like pain, disfigurement, and muscle weakness.
The KOMET trial, the largest and only placebo-controlled study in this population, enrolled 145 adults globally and confirmed Koselugos efficacy and safety profile, consistent with its established use in pediatric patients. Prof. Pierre Wolkenstein highlighted the trials robust findings, emphasizing the drugs ability to close treatment gaps for adults. Marc Dunoyer, CEO of Alexion (AstraZeneca Rare Disease), underscored the approvals importance in extending life-changing treatment options to adults with NF1 PN.
Koselugo, a selective MEK inhibitor, works by slowing tumor growth in NF1, a rare genetic condition affecting up to 50% of patients with PN. The drug has already been approved in Japan and other countries for adults and is approved in the US, EU, Japan, China, and elsewhere for pediatric NF1 patients. The collaboration between AstraZeneca and MSD further supports the development of Koselugo and other innovative treatments.
This approval reinforces AstraZeneca and Alexions commitment to advancing therapies for rare diseases, with Koselugo now available to adult NF1 patients across Europe.
AZN 06:01
AstraZeneca PLC
Tezspire Approved in EU for CRSwNP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Amgens Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on therapy for adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not responded adequately to standard treatments. The approval is based on positive results from the WAYPOINT Phase III trial, which demonstrated significant reductions in nasal polyp severity, nasal congestion, and the need for surgery and systemic corticosteroids compared to placebo. This approval expands Tezspires use beyond severe asthma, highlighting its innovative mechanism targeting thymic stromal lymphopoietin (TSLP), a key driver of epithelial-driven inflammation. CRSwNP affects approximately 320 million people globally, with nearly half of European patients remaining uncontrolled despite current therapies. Tezspires safety profile in the trial was consistent with its known profile, with the most common adverse events being COVID-19, nasopharyngitis, and upper respiratory tract infection. The drug is also approved in the US for CRSwNP and severe asthma, with ongoing regulatory reviews in other countries and Phase III trials in COPD and eosinophilic esophagitis.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
AZN 06:06
AstraZeneca PLC
US FDA Approves Tezspire in CRSwNP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Amgens **Tezspire (tezepelumab)** has received **US FDA approval** for the **add-on maintenance treatment** of **chronic rhinosinusitis with nasal polyps (CRSwNP)** in adults and adolescents aged 12 and older. This approval expands Tezspires indication beyond severe asthma, marking it as the **first and only biologic targeting thymic stromal lymphopoietin (TSLP)** for CRSwNP. The decision was based on positive results from the **WAYPOINT Phase III trial**, which demonstrated significant reductions in nasal polyp severity, near-elimination of surgery needs, and decreased systemic corticosteroid use compared to placebo. CRSwNP affects approximately **320 million people globally**, causing persistent inflammation, nasal obstruction, and impaired quality of life. Tezspires approval offers a novel treatment option for patients with limited relief from current therapies. The drug is also under regulatory review in the **EU, China, Japan, and other countries** for CRSwNP, with ongoing Phase III trials exploring its use in **COPD and eosinophilic esophagitis (EoE)**. AstraZeneca and Amgen continue their collaboration, sharing costs and profits for Tezspires development and commercialization.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 10
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.
AZN 15:01
AstraZeneca PLC
Result of General Meeting
AZN 14:01
AstraZeneca PLC
Total Voting Rights
AZN 06:06
AstraZeneca PLC
Director Declaration
AZN 06:01
AstraZeneca PLC
Koselugo (selumetinib) approved in the EU
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Koselugo (selumetinib) has been approved in the European Union (EU) for treating symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1). The approval is based on positive results from the KOMET Phase III trial, which demonstrated a 20% objective response rate in tumor size reduction compared to 5% with placebo. This marks a significant advancement in addressing unmet needs for adult NF1 patients, as PN can cause severe symptoms like pain, disfigurement, and muscle weakness.
The KOMET trial, the largest and only placebo-controlled study in this population, enrolled 145 adults globally and confirmed Koselugos efficacy and safety profile, consistent with its established use in pediatric patients. Prof. Pierre Wolkenstein highlighted the trials robust findings, emphasizing the drugs ability to close treatment gaps for adults. Marc Dunoyer, CEO of Alexion (AstraZeneca Rare Disease), underscored the approvals importance in extending life-changing treatment options to adults with NF1 PN.
Koselugo, a selective MEK inhibitor, works by slowing tumor growth in NF1, a rare genetic condition affecting up to 50% of patients with PN. The drug has already been approved in Japan and other countries for adults and is approved in the US, EU, Japan, China, and elsewhere for pediatric NF1 patients. The collaboration between AstraZeneca and MSD further supports the development of Koselugo and other innovative treatments.
This approval reinforces AstraZeneca and Alexions commitment to advancing therapies for rare diseases, with Koselugo now available to adult NF1 patients across Europe.
AZN 06:01
AstraZeneca PLC
Tezspire Approved in EU for CRSwNP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Amgens Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on therapy for adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not responded adequately to standard treatments. The approval is based on positive results from the WAYPOINT Phase III trial, which demonstrated significant reductions in nasal polyp severity, nasal congestion, and the need for surgery and systemic corticosteroids compared to placebo. This approval expands Tezspires use beyond severe asthma, highlighting its innovative mechanism targeting thymic stromal lymphopoietin (TSLP), a key driver of epithelial-driven inflammation. CRSwNP affects approximately 320 million people globally, with nearly half of European patients remaining uncontrolled despite current therapies. Tezspires safety profile in the trial was consistent with its known profile, with the most common adverse events being COVID-19, nasopharyngitis, and upper respiratory tract infection. The drug is also approved in the US for CRSwNP and severe asthma, with ongoing regulatory reviews in other countries and Phase III trials in COPD and eosinophilic esophagitis.
AZN 06:06
AstraZeneca PLC
US FDA Approves Tezspire in CRSwNP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Amgens **Tezspire (tezepelumab)** has received **US FDA approval** for the **add-on maintenance treatment** of **chronic rhinosinusitis with nasal polyps (CRSwNP)** in adults and adolescents aged 12 and older. This approval expands Tezspires indication beyond severe asthma, marking it as the **first and only biologic targeting thymic stromal lymphopoietin (TSLP)** for CRSwNP. The decision was based on positive results from the **WAYPOINT Phase III trial**, which demonstrated significant reductions in nasal polyp severity, near-elimination of surgery needs, and decreased systemic corticosteroid use compared to placebo. CRSwNP affects approximately **320 million people globally**, causing persistent inflammation, nasal obstruction, and impaired quality of life. Tezspires approval offers a novel treatment option for patients with limited relief from current therapies. The drug is also under regulatory review in the **EU, China, Japan, and other countries** for CRSwNP, with ongoing Phase III trials exploring its use in **COPD and eosinophilic esophagitis (EoE)**. AstraZeneca and Amgen continue their collaboration, sharing costs and profits for Tezspires development and commercialization.
AZN 06:01
AstraZeneca PLC
Positive CHMP opinion for subcutaneous Saphnelo
AZN 06:01
AstraZeneca PLC
Agreement with US Govt to lower medicine prices
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
AZN 06:01
AstraZeneca PLC
Baxdrostat met primary endpoint in Bax24 Ph3 trial

AI Crunch

Single-Ticker AI Crunch
AZN signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for AstraZeneca PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AZN AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for AZN on 2025-11-06.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
231353303040
Enterprise Value
188046885670
Public Float
99.52
Broker Target
16212.231
Shares Out
1550833276
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB0009895292
Market
LSE - MAIN MARKET
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
2.36
Ex Divi
2026-02-19
Earnings Date
2026-02-05
Net Debt
23911000000.0
Cash
5711000000.0
EPS
4.89
Net Income
10225000000.0
Revenue
58739000000.0
Enterprise Value
188046885670
Trailing PE
30.5072
Forward PE
19.2308
Price Sales TTM
3.9387
Price Book MRQ
6.2017
EV Revenue
5.6989
EV EBITDA
17.1614

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.9735
Institutions As Of
2025-12-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
5
Sale Director Dealing
2
Purchase TR1
3
Sale TR1
3
Broker Coverage Rows
38
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit AZN.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-11-06 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
AstraZeneca PLC has fresh news flow feeding the chart narrative.
AI Charts Studio
AZN Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-11-06 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 13.16%
RSI Gauge
Price Change
AI Forecast